Chronic Hepatitis News

As viral hepatitis continues to be a major health concern in the infectious disease field, recent research has highlighted the importance of testing and treatment.

BOSTON — A regimen of sofosbuvir/velpatasvir with ribavirin was effective among patients with refractory chronic hepatitis C virus with liver cirrhosis and chronic kidney disease, according to data presented at The Liver Meeting.

Tenofovir disoproxil improved long-term overall and recurrence-free survival rates compared with entecavir among patients with hepatitis B virus-related hepatocellular carcinoma who underwent liver resection.

BOSTON — Mortality rates were consistently lower in patients with severe alcohol-associated hepatitis treated with steroids during vs. before the COVID-19 pandemic, suggesting infection mitigation may have benefited this population.

BOSTON — Triple combination of vebicorvir, imdusiran and nucleos(t)ide reverse transcriptase inhibitor did not improve markers of active hepatitis B infection in virologically suppressed patients vs. treatment regimens without vebicorvir.

After assessing a national cohort of U.S. veterans with chronic hepatitis B, researchers found that only about half were on antiviral therapy, although they identified some potential factors associated with lack of timely treatment.

Alcohol use at initiation of direct-acting antiviral treatment was not associated with reduced odds for achieving sustained virologic response among veterans with chronic hepatitis C virus infection, according to data in JAMA Network Open.

Maternal hepatitis B virus serostatus was not associated with pregnancy outcomes in infertile women in China who underwent freeze-thaw embryo transfer, according to data in JAMA Network Open.

Bolstering the introduction of hepatitis B birth dose vaccines and verifying progress in eliminating mother-to-child transmission are among strategies critical to achieving hepatitis B virus control in Africa, WHO and CDC researchers wrote.

The small-interfering RNA JNJ-3989 induced a dose-dependent response for meeting nucleos(t)ide analogue-stopping criteria in patients with chronic hepatitis B virus infection, although hepatitis B surface antigen seroclearance was rare.